New CSF Biomarkers for Alzheimer's Disease (BioAD)

C

Central Hospital, Nancy, France

Status

Enrolling

Conditions

Alzheimer Disease
Neurodegenerative Diseases
Dementia

Study type

Observational

Funder types

Other

Identifiers

NCT03621839
2012-PSS/COLL- LCR/ARMAND/MS

Details and patient eligibility

About

Today, the Alzheimer's disease (AD) diagnosis is founded not only on clinical criteria but also on complementary examinations to confirm a physiopathological process of AD. In complex cases, lumbar punction could be necessary in order to measure Aβ peptides and Total and phosphorylated Tau but new biomarkers could be useful. The main objective of this project is to conserve these cerebrospinal fluids, collected in usual practice in order to validate new biomarkers for diagnosis, prognosis or therapeutic following of Alzheimer's disease and other dementia.

Enrollment

50,000 estimated patients

Sex

All

Volunteers

No Healthy Volunteers

Inclusion criteria

Lumbar punction collected in usual practice in the context of dementia diagnosis

Exclusion criteria

Absence of consent

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems